www.tickerreport.com ·
Vericel Nasdaqvcel Announces Quarterly Earnings Results
Topic context
This topic has been covered 366878 times in the last 30 days across our monitored publishers.
The full article is on the original publisher site. This page only shows the headline and a very short excerpt.
AI insight
AI-generatedVericel (VCEL) beat Q1 estimates on revenue and raised full-year guidance. FDA approval for Burlington facility supports U.S. growth and MACI supply. U.K. submission expands geographic reach. Company-specific positive earnings and regulatory catalyst; no broad sector or commodity impact.
Signals our AI researcher identified
Extracted by our AI model from this article and related public sources — not direct quotes from the publisher.
- Vericel reported Q1 2026 EPS of -$0.12 vs -$0.15 consensus
- Revenue $68.43M vs $63.68M consensus, +30.1% YoY
- Raised 2026 revenue guidance by $10M to $326M-$336M
- FDA approved commercial manufacturing at new Burlington facility
- Planned U.K. marketing submission for MACI in 2026
FDA approval of Burlington facility supports margin expansion in 2-4 quarters.
Sign in to see all sector verdicts, full thesis and counter-argument debate.
Sector impact at a glance
- PHARMA_BIOTECHmid
- PHARMA_BIOTECHshort
Related stories
fool.com
Keysight Keys Q2 2026 Earnings Transcript
proactiveinvestors.com.au
The Morning Catch Up Asx Set to Open Lower Ahead of Pivotal Nvidia Earnings
tickerreport.com
Roivant Sciences Nasdaqroiv Shares Gap Up on Strong Earnings
nbclosangeles.com
Spacex Confirms Plans for IPO
finance.yahoo.com